FDA Readies Proposed Rule On Combination Products Postmarket Reporting
This article was originally published in The Gray Sheet
Executive Summary
A proposed rule wending its way through regulatory review at FDA would clarify postmarket safety reporting requirements for makers of combination products
You may also be interested in...
Office Of Combination Products Keeps Up Work To Clarify Regulatory Process
FDA's Office of Combination Products says it is working hard to provide industry with a clearer framework for bringing technologies that unite drugs, devices and biologics to market
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”